AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Biochemical and Biophysical Research Communications

Volumn 391, Issue 1, 2010, Pages 147-151

  Choi, Jae Sun ^a   Park, Chan ^a   Jeong, Joo Won ^a  

^a Biomedical Science Institute   (South Korea)

Author keywords

AMPK; MPP+; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SURVIVAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DOPAMINE AGENTS; ENZYME ACTIVATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEURONS; PARKINSON DISEASE;

MUS;

EID: 72949122084     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.11.022     Document Type: Article

References (25)

1. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55 (1996) 259-272
2. Tretter L., Sipos I., and Adam-Vizi V. Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. Neurochem. Res. 29 (2004) 569-577
3. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S26-S36 (discussion S36-S38)
4. Dipasquale B., Marini A.M., and Youle R.J. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. Biochem. Biophys. Res. Commun. 181 (1991) 1442-1448
5. Smeyne R.J., and Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 134 (2005) 57-66
6. Borsello T., and Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr. Pharm. Des. 13 (2007) 1875-1886
7. Karunakaran S., Saeed U., Mishra M., Valli R.K., Joshi S.D., Meka D.P., Seth P., and Ravindranath V. Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J. Neurosci. 28 (2008) 12500-12509
8. Oakhill J.S., Scott J.W., and Kemp B.E. Structure and function of AMP-activated protein kinase. Acta Physiol. (Oxf.) (2009)
9. Hawley S.A., Davison M., Woods A., Davies S.P., Beri R.K., Carling D., and Hardie D.G. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 271 (1996) 27879-27887
10. Birnbaum M.J. Activating AMP-activated protein kinase without AMP. Mol. Cell 19 (2005) 289-290
11. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., Frenguelli B.G., and Hardie D.G. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2 (2005) 9-19
12. Jung S.N., Yang W.K., Kim J., Kim H.S., Kim E.J., Yun H., Park H., Kim S.S., Choe W., Kang I., and Ha J. Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis 29 (2008) 713-721
13. Park I.J., Hwang J.T., Kim Y.M., Ha J., and Park O.J. Differential modulation of AMPK signaling pathways by low or high levels of exogenous reactive oxygen species in colon cancer cells. Ann. N. Y. Acad. Sci. 1091 (2006) 102-109
14. Weekes J., Hawley S.A., Corton J., Shugar D., and Hardie D.G. Activation of rat liver AMP-activated protein kinase by kinase kinase in a purified, reconstituted system. Effects of AMP and AMP analogues. Eur. J. Biochem. 219 (1994) 751-757
15. Suwa M., Nakano H., and Kumagai S. Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J. Appl. Physiol. 95 (2003) 960-968
16. Fryer L.G., Hajduch E., Rencurel F., Salt I.P., Hundal H.S., Hardie D.G., and Carling D. Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes 49 (2000) 1978-1985
17. Chen Z.P., McConell G.K., Michell B.J., Snow R.J., Canny B.J., and Kemp B.E. AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am. J. Physiol. Endocrinol. Metab. 279 (2000) E1202-E1206
18. Blazquez C., Geelen M.J., Velasco G., and Guzman M. The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett. 489 (2001) 149-153
19. Culmsee C., Monnig J., Kemp B.E., and Mattson M.P. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J. Mol. Neurosci. 17 (2001) 45-58
20. McCullough L.D., Zeng Z., Li H., Landree L.E., McFadden J., and Ronnett G.V. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J. Biol. Chem. 280 (2005) 20493-20502
21. Kim Y.S., Ahn K.H., Kim S.Y., and Jeong J.W. Okadaic acid promotes angiogenesis via activation of hypoxia-inducible factor-1. Cancer Lett. 276 (2009) 102-108
22. Ehrhanrdt C., Schmolke M., Matzke A., Knoblauch A., Will C., Wixler V., and Ludwing S. Polyethylenimine, a cost-effective transfection reagent. Signal Transduct. 6 (2006) 179-184
23. Jackson-Lewis V., and Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2 (2007) 141-151
24. Rong Y., Belozerov V.E., Tucker-Burden C., Chen G., Durden D.L., Olson J.J., Van Meir E.G., Mackman N., and Brat D.J. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 69 (2009) 2540-2549
25. Stull N.D., Polan D.P., and Iacovitti L. Antioxidant compounds protect dopamine neurons from death due to oxidative stress in vitro. Brain Res. 931 (2002) 181-185